Infectious Diseases in Obstetrics and Gynecology antiviral treatment of patients with recurrent genital herpes,” Journal of Clinical Microbiology, vol. 34, no. 3, pp. 657–663, 1996. [17] S. E. Straus, J. F. Rooney, and C. Hallahan, “Acyclovir suppresses subclinical shedding of herpes simplex virus,” Annals of Internal Medicine, vol. 125, no. 9, pp. 776–777, 1996. [18] H. H. Handsﬁeld, T. Warren, M. Werner, and J. A. Phillips, “Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical eﬃcacy and herpes-related quality of life,” Sexually Transmitted Diseases, vol. 34, no. 6, pp. 339–343, 2007. [19] K. H. Fife, T. J. Warren, S. E. Justus, and C. K. Heitman, “An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients,” Sexually Transmitted Diseases, vol. 35, no. 7, pp. 668–673, 2008. [20] A. J. Ryncarz, J. Goddard, A. Wald, M.-L. Huang, B. Roizman, and L. Corey, “Development of a high-throughput quantita- tive assay for detecting herpes simplex virus DNA in clinical samples,” Journal of Clinical Microbiology, vol. 37, no. 6, pp. 1941–1947, 1999. [21] G. G. Koch, “The use of non-parametric methods in the statistical analysis of the two-period change-over design,” Biometrics, vol. 28, no. 2, pp. 577–584, 1972. [22] S. Senn, Crossover Trials in Clinical Trial Research, John Wiley & Sons, London, UK, 2nd edition, 2002. [23] D. M. Koelle, J. Benedetti, A. Langenberg, and L. Corey, “Asymptomatic reactivation of herpes simplex virus in women after the ﬁrst episode of genital herpes,” Annals of Internal Medicine, vol. 116, no. 6, pp. 433–437, 1992. 7